Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM
Minerva endocrinology Pub Date : 2023-06-01 Epub Date: 2020-07-23 DOI:10.23736/S2724-6507.20.03219-8
Besmir Nreu, Ilaria Dicembrini, Federico Tinti, Edoardo Mannucci, Matteo Monami
{"title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.","authors":"Besmir Nreu, Ilaria Dicembrini, Federico Tinti, Edoardo Mannucci, Matteo Monami","doi":"10.23736/S2724-6507.20.03219-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>An association between glucagon-like peptide-1 receptor agonists (GLP1-RA) and risk of pancreatitis and pancreatic cancer has been suggested. Since its first description, several new trials (including three cardiovascular outcome trials) have been published, substantially increasing the available data set. This suggests the need for an update of the previous meta-analysis.</p><p><strong>Evidence acquisition: </strong>A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials, with duration ≥52 weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with placebo or any other non-GLP-1 receptor agonist drug. The endpoints were pancreatitis, pancreatic cancer reported as serious adverse events. Mantel-Haenszel Odds Ratio (MH-OR) with 95% confidence interval (95% CI) was calculated for all outcomes defined above, on an intention-to-treat basis.</p><p><strong>Evidence synthesis: </strong>A total of 43 trials fulfilling inclusion criteria (all reporting data on pancreatitis and pancreatic cancer) was identified. GLP-1 RA showed no association with pancreatitis (MH-OR 1.24 [0.94, 1.64]; P=0.13) and pancreatic cancer (MH-OR 1.28 [0.87, 1.89]; P=0.20).</p><p><strong>Conclusions: </strong>No clear evidence of risk for pancreatitis was observed, whereas data on pancreatic cancer are too scarce to draw any conclusion.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S2724-6507.20.03219-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/7/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: An association between glucagon-like peptide-1 receptor agonists (GLP1-RA) and risk of pancreatitis and pancreatic cancer has been suggested. Since its first description, several new trials (including three cardiovascular outcome trials) have been published, substantially increasing the available data set. This suggests the need for an update of the previous meta-analysis.

Evidence acquisition: A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials, with duration ≥52 weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with placebo or any other non-GLP-1 receptor agonist drug. The endpoints were pancreatitis, pancreatic cancer reported as serious adverse events. Mantel-Haenszel Odds Ratio (MH-OR) with 95% confidence interval (95% CI) was calculated for all outcomes defined above, on an intention-to-treat basis.

Evidence synthesis: A total of 43 trials fulfilling inclusion criteria (all reporting data on pancreatitis and pancreatic cancer) was identified. GLP-1 RA showed no association with pancreatitis (MH-OR 1.24 [0.94, 1.64]; P=0.13) and pancreatic cancer (MH-OR 1.28 [0.87, 1.89]; P=0.20).

Conclusions: No clear evidence of risk for pancreatitis was observed, whereas data on pancreatic cancer are too scarce to draw any conclusion.

接受胰高血糖素样肽-1 受体激动剂治疗的 2 型糖尿病患者的胰腺炎和胰腺癌:随机对照试验的最新荟萃分析。
简介:胰高血糖素样肽-1 受体激动剂(GLP1-RA)与胰腺炎和胰腺癌风险之间存在关联。自首次描述以来,又有几项新的试验(包括三项心血管结果试验)发表,大大增加了现有的数据集。这表明有必要对之前的荟萃分析进行更新:对GLP-1受体激动剂(艾塞那肽、利拉鲁肽、利西那肽、阿比格鲁肽、度拉鲁肽或赛马鲁肽)进行了Medline检索,收集了所有随机临床试验,试验持续时间≥52周,入选者为2型糖尿病患者,并比较了GLP-1受体激动剂与安慰剂或任何其他非GLP-1受体激动剂药物。研究终点为胰腺炎、胰腺癌等严重不良事件。在意向治疗的基础上,对上述所有结果计算了曼特尔-海恩泽尔比值比(MH-OR)及95%置信区间(95% CI):共确定了 43 项符合纳入标准的试验(均报告了有关胰腺炎和胰腺癌的数据)。GLP-1 RA与胰腺炎(MH-OR 1.24 [0.94, 1.64];P=0.13)和胰腺癌(MH-OR 1.28 [0.87, 1.89];P=0.20)没有关联:没有观察到胰腺炎风险的明确证据,而有关胰腺癌的数据太少,无法得出任何结论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.60
自引率
0.00%
发文量
146
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信